Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW

Feasibility of ex vivo fluorescence imaging of angiogenesis in (non-) culprit human carotid atherosclerotic plaques using bevacizumab-800CW

Abstract Vascular endothelial growth factor-A (VEGF-A) is assumed to play a crucial role in the development and rupture of vulnerable plaques in the atherosclerotic process. We used a VEGF-A targeted fluorescent antibody (bevacizumab-IRDye800CW [bevacizumab-800CW]) to image and visualize the distrib...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lydian A. Huisman, Pieter J. Steinkamp, Jan-Luuk Hillebrands, Clark J. Zeebregts, Matthijs D. Linssen, Annelies Jorritsma-Smit, Riemer H. J. A. Slart, Gooitzen M. van Dam, Hendrikus H. Boersma
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/90bcd3fa4abc46a1b524b9280ad22262
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares